Clinical trial
Oral Decitabine-Based Maintenance Therapy in Patients With AML in Remission
NCT05010772 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Oral Decitabine-Based Maintenance Therapy in Patients With AML in Remission
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 25, 2021
- Completion date
- December 31, 2026
- Enrollment
- 125 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia